PT998501E - Polimeros cationicos complexos associando os referidos polimeros cationicos e substancias terapeuticamente activas compreendendo pelo menos uma carga negativa especialmente acidos nucleicos e sua utilizacao em terapia genica - Google Patents

Polimeros cationicos complexos associando os referidos polimeros cationicos e substancias terapeuticamente activas compreendendo pelo menos uma carga negativa especialmente acidos nucleicos e sua utilizacao em terapia genica

Info

Publication number
PT998501E
PT998501E PT98939713T PT98939713T PT998501E PT 998501 E PT998501 E PT 998501E PT 98939713 T PT98939713 T PT 98939713T PT 98939713 T PT98939713 T PT 98939713T PT 998501 E PT998501 E PT 998501E
Authority
PT
Portugal
Prior art keywords
gene therapy
negative charge
therapeutically active
comprehending
cationic
Prior art date
Application number
PT98939713T
Other languages
English (en)
Inventor
Hanno V J Kolbe
Thierry Delair
Otmane Boussif
Laurent Veron
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9709209A external-priority patent/FR2766194A1/fr
Application filed by Transgene Sa filed Critical Transgene Sa
Publication of PT998501E publication Critical patent/PT998501E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F126/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F126/02—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00—Chemical modification by after-treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Polymers & Plastics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
PT98939713T 1997-07-21 1998-07-20 Polimeros cationicos complexos associando os referidos polimeros cationicos e substancias terapeuticamente activas compreendendo pelo menos uma carga negativa especialmente acidos nucleicos e sua utilizacao em terapia genica PT998501E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9709209A FR2766194A1 (fr) 1997-07-21 1997-07-21 Polymeres cationiques, complexes associant lesdits polymeres cationiques et des substances therapeutiquement actives comprenant au moins une charge negative, notamment des acides nucleiques, et leur utilisation en therapie genique
FR9715807A FR2766195A1 (fr) 1997-07-21 1997-12-12 Polymeres cationiques, complexes associant lesdits polymeres cationiques et des substances therapeutiquement actives comprenant au moins une charges negative, notamment des acides nucleiques, et leur utilisation en therapie genique

Publications (1)

Publication Number Publication Date
PT998501E true PT998501E (pt) 2002-08-30

Family

ID=26233691

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98939713T PT998501E (pt) 1997-07-21 1998-07-20 Polimeros cationicos complexos associando os referidos polimeros cationicos e substancias terapeuticamente activas compreendendo pelo menos uma carga negativa especialmente acidos nucleicos e sua utilizacao em terapia genica

Country Status (12)

Country Link
US (1) US6407178B1 (pt)
EP (1) EP0998501B1 (pt)
JP (1) JP2001510863A (pt)
AT (1) ATE215099T1 (pt)
AU (1) AU740392B2 (pt)
CA (1) CA2297487A1 (pt)
DE (1) DE69804463T2 (pt)
DK (1) DK0998501T3 (pt)
ES (1) ES2172180T3 (pt)
FR (1) FR2766195A1 (pt)
PT (1) PT998501E (pt)
WO (1) WO1999005183A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030134420A1 (en) * 2000-02-18 2003-07-17 Lollo Charles Peter Methods and compositions for gene delivery
WO2002032396A2 (en) * 2000-10-16 2002-04-25 Massachusetts Institute Of Technology Lipid-protein-sugar particles for delivery of nucleic acids
AU2002257145B2 (en) * 2001-04-18 2005-06-02 Genzyme Corporation Method for lowering serum glucose
AU2003240978A1 (en) * 2002-05-31 2003-12-19 Genteric, Inc. Multi-functional polyamines for delivery of biologically-active polynucleotides
US20040077888A1 (en) * 2002-05-31 2004-04-22 The Regents Of The University Of California Polyamine-mediated transfection
DE10310196A1 (de) * 2003-03-06 2004-09-23 Rina-Netzwerk Rna Technologien Gmbh Verwendung eines trizyklischen Antidepressivums zur Förderung der Endozytose
AU2004260935A1 (en) * 2003-06-30 2005-02-10 Canji, Inc. Polymer encapsulation of adenoviruses
CA2543257C (en) 2003-10-24 2013-12-31 Gencia Corporation Methods and compositions for delivering polynucleotides
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US20070176158A1 (en) * 2006-02-01 2007-08-02 Robinson Jeffery A Portable safety barrier
US8686129B2 (en) * 2007-03-20 2014-04-01 Agilent Technologies, Inc. Methods for the separation of biological molecules using sulfolane
US8357531B2 (en) 2007-07-03 2013-01-22 Transgene S.A. Immortalized avian cell lines
CN101970012A (zh) * 2007-09-14 2011-02-09 日东电工株式会社 药物载体
US8722348B2 (en) * 2008-05-28 2014-05-13 Wayne State University Method and composition for a protein transduction technology and its applications
AU2015270888B2 (en) * 2008-05-28 2017-11-16 Wayne State University Method and composition for a protein transduction technology and its applications
CA2934065C (en) 2013-10-25 2023-05-09 Qurgen, Inc. Methods, systems and compositions relating to cell conversion via protein-induced in-vivo cell reprogramming

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3440320A (en) * 1964-06-18 1969-04-22 Mortimer D Sackler Chelated suppository and method of using same
US3325472A (en) * 1964-06-18 1967-06-13 Mortimer D Sackler Polycyclohexose-polyoxyethyleneglycol suppository bases
JPS60106804A (ja) * 1983-11-15 1985-06-12 Nitto Boseki Co Ltd ポリアリルアミンから誘導される新規な機能性樹脂
US4908404A (en) * 1988-08-22 1990-03-13 Biopolymers, Inc. Synthetic amino acid-and/or peptide-containing graft copolymers
SE467309B (sv) * 1990-10-22 1992-06-29 Berol Nobel Ab Hydrofiliserad fast yta, foerfarande foer dess framstaellning samt medel daerfoer
ATE159262T1 (de) * 1992-07-22 1997-11-15 Hoechst Ag Hydrophile zentren aufweisende polyvinylamin- derivate, verfahren zu ihrer herstellung sowie die verwendung der verbindungen als arzneimittel, wirkstoffträger und nahrungsmittelhilfsstoff
DK0580079T3 (da) * 1992-07-22 1997-06-30 Hoechst Ag Tværbundne, nitrogenholdige vinylcopolymerer, fremgangsmåde til deres fremstilling samt anvendelse af disse forbindelser
DE4227019A1 (de) * 1992-08-14 1994-02-17 Geckeler Kurt E Priv Doz Dr Herstellung und Modifikation von Materialien auf der Basis von Amino- oder Amidpolymeren
DE4322884A1 (de) * 1992-10-09 1994-04-14 Bayer Ag Biologisch aktive Polymere
US5260385A (en) * 1992-11-02 1993-11-09 Director-General Of Agency Of Industrial Science And Technology Biguanide group-containing polyallylamine and method of producing same
CA2167920A1 (en) * 1993-07-23 1995-02-02 Abraham J. Domb Nonoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US5629184A (en) * 1995-01-25 1997-05-13 Amgen Inc. Cationic copolymers of vinylamine and vinyl alcohol for the delivery of oligonucleotides

Also Published As

Publication number Publication date
ES2172180T3 (es) 2002-09-16
FR2766195A1 (fr) 1999-01-22
CA2297487A1 (fr) 1999-02-04
DE69804463T2 (de) 2002-10-10
US6407178B1 (en) 2002-06-18
AU740392B2 (en) 2001-11-01
US20020031763A1 (en) 2002-03-14
AU8813198A (en) 1999-02-16
EP0998501A1 (fr) 2000-05-10
DE69804463D1 (de) 2002-05-02
JP2001510863A (ja) 2001-08-07
DK0998501T3 (da) 2002-07-01
EP0998501B1 (fr) 2002-03-27
ATE215099T1 (de) 2002-04-15
WO1999005183A1 (fr) 1999-02-04

Similar Documents

Publication Publication Date Title
PT998501E (pt) Polimeros cationicos complexos associando os referidos polimeros cationicos e substancias terapeuticamente activas compreendendo pelo menos uma carga negativa especialmente acidos nucleicos e sua utilizacao em terapia genica
BR9914643A (pt) Vetores adeno-associados para expressão dofator viii por células alvo
BR9810369A (pt) Processo de transferência de ácido nucleico para o interior de um ou mais músculos estriados, in vivo, composição, ácido mucleico e campo elétrico, e, produto de combinação
ATE334664T1 (de) Zelldurchlässige peptide zur inhibierung von entzündungsreaktionen und deren verwendung
ES2147553T3 (es) Vectores virales recombinantes para la expresion en unas celulas musculares.
DE3650753D1 (de) Auf einmaligen sequenzen innerhalb des veränderlichen gebiets des t-zellrezeptors basierte diagnosemittel und deren verwendung
DE69635609D1 (de) Nukleinsäure enthaltende zusammensetzung, herstellung und verwendung
BR9813202B1 (pt) complexo de administração de genes; processo de transdução de células com material genético estranho, composição útil para administração de material genético e uso de um complexo de administração de genes.
EP0892644A4 (en) -i(IN VIVO) GENE TRANSFER METHODS FOR WOUND HEALING
DE69840165D1 (de) Genkonstrukt das für ein heterologes "prodrug"-aktivierendes enzym und für ein zellgerichtes teil kodiert
BR9809506A (pt) Composto, composição, utilização de um composto, e, processos para preparação de um composto e para transferência de ácidos nucleicos para o interior das células
FR2738151B1 (fr) Antagonistes de l'activite oncogenique de la proteine mdm2, et leur utilisation dans le traitement des cancers
TR199802649A2 (xx) Sikline ba�l� kinazlar�n inhibit�rleri i�in ba�lama e�leri.
Katayama et al. Intracellular signal-responsive artificial gene regulation for novel gene delivery
ATE99669T1 (de) N-2,3-butadienyl-tri-aminoalkanderivate.
EP0689586A4 (en) FUNCTION AND ACTIVITY OF VIRAL PROTEIN R (VPR)
ATE90354T1 (de) Polydeoxyribonukleotide, pharmazeutische zusammensetzungen, verwendung und herstellung von polydeoxyribonukleotiden.
DE3673436D1 (de) Gene fuer biologisch aktive proteine.
BR9909044A (pt) Vetor de tranferência de ácidos nucleicos, composição, utilização de um vetor de tranferência de ácidos nucleicos, processos de transfecção de ácidos nucleicos nas células, e de tratamento de doenças, e, célula recombinante
DE3577994D1 (de) Vergroessernde virale dna-segmente.
ES468918A1 (es) Procedimiento para la preparacion de complejos de peptido
DE50009932D1 (de) Gentransfer in humane lymphocyten mittels retroviraler scfv-zelltargeting vektoren
PT840794E (pt) Medicamento contendo pelo menos uma parte da proteina ul84 do citomegalovirus, utilizacao de polipeptideos de acordo com a sequencia do aminoacido da proteina ul84 e processo para a introducao de ul84 em celulas alvo
ATE66602T1 (de) Verwendung von nitrophenylgruppen zur stimulierung der inkorporationsfaehigkeit eines arzneimittels in die empfindlichen wirtszellen.
WO1993013204A3 (de) Mittel zur stimulierung der teilungsaktivität tierischer zellen